GoldenGolden
Advanced Search
Induced pluripotent stem cell

Induced pluripotent stem cell

Induced Pluripotent Stem Cells, abbreviated as iPS cells or iPSCs, are generated in the laboratory by treating adult differentiated cells from sources such as skin, with factors that reprogram the cells to an undifferentiated pluripotent state. The cells can then be treated with factors that signal the cells to differentiate into another cell type.

All edits

Edits on 29 Apr, 2020
Golden AI"Attach Wikidata entity ID"
Golden AI edited on 29 Apr, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Wikidata entity ID
Q674925
Edits on 3 Jul, 2019
Carla Faraguna
Carla Faraguna edited on 3 Jul, 2019
Edits made to:
Companies (+85/-85 characters)
Companies

Company
CEO
Location
Products/Services

CelgeneCelgene

Cellular Dynamics InternationalCellular Dynamics International

EvotecEvotec

Horizon DiscoveryHorizon Discovery

Thermo Fisher ScientificThermo Fisher Scientific

Edits on 17 Jan, 2019
Meredith Hanel
Meredith Hanel edited on 17 Jan, 2019
Edits made to:
Article (+3 characters)
Article

The two main applications from iPS cells are cell replacement therapy and drug discovery. An example of cell replacement therapy is to grow pancreas cells to transplant into patients with type I diabetes, where the immune system has destroyed the beta cells that produce insulin. For drug discovery research, iPS cells derived from patients with or without a certain disease can be differentiated into cell and tissue types in order to model and understand the disease at the molecular level. These disease models can be used to identify drug targets and test potential therapies.

Edits on 30 Nov, 2018
Melanie Manipula"moved companies to table"
Melanie Manipula edited on 30 Nov, 2018
Edits made to:
Article (-205 characters)
Companies (+10 rows) (+10 cells) (+151 characters)
Article

Companies developing iPS cells and related technology
  • Evotec
  • Sanofi
  • Censo Biotechnologies
  • Celgene
  • Axol Bioscience
  • Takeda
  • iPS Academia Japan
  • Thermo Fisher Scientific
  • Horizon Discovery
  • Cellular Dynamics International

Companies

Company
CEO
Location
Products/Services

Axol Bioscience

Celgene

Cellular Dynamics International

Censo Biotechnologies

Evotec

Horizon Discovery

iPS Academia Japan

Sanofi

Takeda

Thermo Fisher Scientific

Edits on 24 Nov, 2018
Form Icin
Form Icin approved a suggestion from Golden's AI on 24 Nov, 2018
Edits made to:
Article (+12/-12 characters)
Article

Getting these factors into cells in order to reprogram them can be done a number of ways. Retroviruses and lentiviruses, used to deliver these iPS cell programming factors as transgenes, have a risk of causing mutations where they insert into the cell genome. The transgenes are silenced after reprogramming but carry the chance of reactivating which could potentially cause tumors. Adenovirus, plasmid vectors, removable piggyBac transposons and Sendai virusSendai virus have been developed to deliver genes in transient way so they are not integrated into the genome. Certain chemical compounds such as valproic acid, sodium butyrate and histone deacetylase inhibitors have been shown to improve efficiency of iPS cell generation.

Edits on 24 Nov, 2018
Form Icin
Form Icin approved a suggestion from Golden's AI on 24 Nov, 2018
Edits made to:
Article (+18/-18 characters)
Article

In March 2018 Sumitomo Dainippon Pharma opened the world’s first commercial iPS cell plant offering cells for commercial purposes. Their initial production of iPS cells will be for use in clinical trials. Production facilities for iPS cells that are available to researchers include the National Institutes of Health Center for Regenerative Medicine and the stem cell bank run by the WiCell Research Institute in Madison, WisconsinMadison, Wisconsin, USA. The European Bank for induced pluripotent Stem Cells supplies iPS cell lines to researchers in academia and industry.

Form Icin
Form Icin approved a suggestion from Golden's AI on 24 Nov, 2018
Edits made to:
Article (+15/-15 characters)
Article

Research into embryonic stem cells, the ability to create a clone of an organism by reprogramming the nucleus of an adult cell and the identification of master regulator genes that maintain cellular identity lead up to the ability to generate pluripotent stem cells from adult cells in the laboratory by supplying certain reprogramming factors. The first mouse iPS cells were generated using a retrovirus to introduce 4 transcription factors, c-Myc, Oct3/4, Sox2 and Klf4 into mouse skin fibroblasts by Shinya YamanakaShinya Yamanaka and his colleagues in 2006. Sox2 controls expression of Oct3/4. c-Myc recruits proteins that modify chromatin to cause widespread activation of gene transcription. c-Myc is also a proto-oncogene associated with causing various cancers. L-Myc can replace c-Myc and does not have the ability to transform cells into tumours.

Meredith Hanel
Meredith Hanel edited on 23 Nov, 2018
Edits made to:
Article (+112 characters)
Article
  • Axol Bioscience
  • Takeda
  • iPS Academia Japan
  • Thermo Fisher Scientific
  • Horizon Discovery
  • Cellular Dynamics International
Meredith Hanel
Meredith Hanel edited on 23 Nov, 2018
Edits made to:
Description (+350 characters)
Article (+2995 characters)
Related Topics (+1 topics)
Topic thumbnail

Induced pluripotent stem cell

Induced Pluripotent Stem Cells, abbreviated as iPS cells or iPSCs, are generated in the laboratory by treating adult differentiated cells from sources such as skin, with factors that reprogram the cells to an undifferentiated pluripotent state. The cells can then be treated with factors that signal the cells to differentiate into another cell type.

Article

iPS cells are useful for research and development of therapies because they are derived from accessible locations such as skin and blood and because they can be maintained in culture and expanded quickly.

Research into embryonic stem cells, the ability to create a clone of an organism by reprogramming the nucleus of an adult cell and the identification of master regulator genes that maintain cellular identity lead up to the ability to generate pluripotent stem cells from adult cells in the laboratory by supplying certain reprogramming factors. The first mouse iPS cells were generated using a retrovirus to introduce 4 transcription factors, c-Myc, Oct3/4, Sox2 and Klf4 into mouse skin fibroblasts by Shinya Yamanaka and his colleagues in 2006. Sox2 controls expression of Oct3/4. c-Myc recruits proteins that modify chromatin to cause widespread activation of gene transcription. c-Myc is also a proto-oncogene associated with causing various cancers. L-Myc can replace c-Myc and does not have the ability to transform cells into tumours.

Getting these factors into cells in order to reprogram them can be done a number of ways. Retroviruses and lentiviruses, used to deliver these iPS cell programming factors as transgenes, have a risk of causing mutations where they insert into the cell genome. The transgenes are silenced after reprogramming but carry the chance of reactivating which could potentially cause tumors. Adenovirus, plasmid vectors, removable piggyBac transposons and Sendai virus have been developed to deliver genes in transient way so they are not integrated into the genome. Certain chemical compounds such as valproic acid, sodium butyrate and histone deacetylase inhibitors have been shown to improve efficiency of iPS cell generation.

In March 2018 Sumitomo Dainippon Pharma opened the world’s first commercial iPS cell plant offering cells for commercial purposes. Their initial production of iPS cells will be for use in clinical trials. Production facilities for iPS cells that are available to researchers include the National Institutes of Health Center for Regenerative Medicine and the stem cell bank run by the WiCell Research Institute in Madison, Wisconsin, USA. The European Bank for induced pluripotent Stem Cells supplies iPS cell lines to researchers in academia and industry.

The two main applications from iPS cells are cell replacement therapy and drug discovery. An example of cell replacement therapy is to grow pancreas cells to transplant into patients with type I diabetes, where the immune system has destroyed the beta cells that produce insulin. For drug discovery research, iPS cells derived from patients with or without a certain disease can differentiated into cell and tissue types in order to model and understand the disease at the molecular level. These disease models can be used to identify drug targets and test potential therapies.

Companies developing iPS cells and related technology
  • Evotec
  • Sanofi
  • Censo Biotechnologies
  • Celgene
Related Topics
Edits on 1 Jan, 2017
Golden AI"Initial topic creation"
Golden AI created this topic on 1 Jan, 2017
Edits made to:
Article
Topic thumbnail

 Induced pluripotent stem cell

Induced Pluripotent Stem Cells, abbreviated as iPS cells or iPSCs, are generated in the laboratory by treating adult differentiated cells from sources such as skin, with factors that reprogram the cells to an undifferentiated pluripotent state. The cells can then be treated with factors that signal the cells to differentiate into another cell type.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.